23 April 2025 in Revista Argentina de Cardiologia
COVID-19. Review on Its Cardiovascular Impact
25 April 2021 in Revista Argentina de Cardiologia
Background: Patients with acute coronary syndrome benefit from the use of antiplatelet agents to reduce the recurrence of ischemic events. For a long time, we have been used to indicate a fixed combination of aspirin plus a P2Y12 receptor inhibitor during a strict period of time. However, the complexity of patients and procedures force us, as physicians, to seek the best possible combinations, both of the type of drugs used as treatment duration, in order to achieve the best balance between ischemic protection and bleeding risk. In recent years, numerous studies carried out in this regard have shown that different strategies may benefit our patients in different settings. In the following review we provide an overview of the current knowledge about antiplatelet therapies, along with some suggestions on their management.
28 March 2025 in Revista Argentina de Cardiologia
Background: There is limited real life information on treatment strategies with P2Y12 receptor inhibitors (P2Y12i) in nonST-segment elevation acute coronary syndromes (NSTEACS). Objectives: The aim of this study was to determine the incidence of major adverse cardiac events (MACE) and BARC bleeding ≥2, according to the treatment strategy with P2Y12i at 6 months. Methods: The study used the pre-specified subanalysis of the BUENOS AIRES I registry (n=1100). The cohort was stratified according to P2Y12i "pretreatment" (before knowing the coronary anatomy), or "ward treatment" (after knowing the coronary anatomy), and the incidence of clinical events was analyzed according to pretreatment or ward treatment with clopidogrel/ticagrelor. Results: Mean age was 65.4 ± 11.5 years and 77.2% were male patients. In 79.72% of cases patients received P2Y12i, 75% as pretreatment and 25% as ward treatment. Pretreatment patients were younger and with greater prevalence of acute myocardial infarction (AMI) compared with the ward treatment subgroup. At 6 months, there were no significant differences in the incidence of MACE (16.4% vs. 14.4%; p = 0.508), or BARC bleeding ≥2 (14.7% vs. 11.1%; p = 0.205), between the different times of P2Y12i administration. Treatment with ticagrelor presented reduced MACE compared with clopidogrel (p = 0.044), with no difference in bleeding. No MACE differences were observed between pretreatment or in ward treatment with ticagrelor (p=0.893). Conclusions: The subgroup of patients selected to receive P2Y12i pretreatment did not present differences in MACE or bleeding relative to those treated in ward. Patients selected for ticagrelor treatment in ward presented a beneficial balance between ischemic and hemorrhagic events.